GlassScriptPhysician profile
Ahmed T Butt
NPI 1003027301
$59,174.90
in general payments reported to CMS, 2019-2025
35 companies · $7,369 in 2025
The $7,369 reported for 2025 was more than what 86% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $1,901 · 2021: $7,388 · 2022: $8,404 · 2023: $13K · 2024: $5,145 · 2025: $7,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $9,679 · Travel and Lodging: $851 · Consulting Fee: $500 · Education: $37.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,400.00 |
| Food and Beverage | $9,679.12 |
| Travel and Lodging | $850.76 |
| Consulting Fee | $500.00 |
| Education | $37.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $29,647.98 | 2019-2025 | |
| Genzyme Corporation | $5,863.71 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $5,502.65 | 2019-2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $5,438.69 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $3,946.58 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $2,443.33 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Optinose US, INC. | $1,220.02 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $593.52 | 2019-2025 | |
| Abbvie INC. | $591.77 | 2022-2024 | Rinvoq |
| Csl Behring | $480.16 | 2019-2025 | Haegarda, Andembry |
| Amgen INC. | $457.12 | 2021-2025 | Tezspire |
| Kaleo, INC. | $436.21 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $365.67 | 2020-2025 | Takhzyro, Cuvitru |
| Genentech USA, INC. | $344.46 | 2019-2024 | Xolair |
| Biocryst US Sales Co., LLC | $325.47 | 2021-2025 | Orladeyo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.60 | 2020-2022 | |
| Alk-Abello, INC | $156.68 | 2019-2023 | Timothy, Standardized, Odactra, Standardized Mite D. Farinae |
| Ars Pharmaceuticals Operations, INC. | $154.63 | 2025 | Neffy |
| Adma Biomanufacturing LLC | $150.00 | 2024 | |
| Leo Pharma INC. | $116.92 | 2022-2023 | Adbry |
| Greer Laboratories, INC. | $111.53 | 2023-2025 | Oralair |
| Pharming Healthcare, INC. | $101.39 | 2021-2024 | Ruconest |
| Incyte Corporation | $97.22 | 2021-2025 | Opzelura |
| Ionis Pharmaceuticals, INC. | $67.21 | 2025 | Dawnzera |
| Grifols USA, LLC | $63.74 | 2022-2024 | Xembify |
| Regeneron Pharmaceuticals, INC. | $58.33 | 2019 | |
| Eyevance Pharmaceuticals LLC | $48.32 | 2021 | |
| Aimmune Therapeutics, INC. | $41.70 | 2022 | |
| Galderma Laboratories, L.P. | $36.23 | 2025 | Nemluvio |
| Uswm, LLC | $32.89 | 2021 | |
| Sanofi-Aventis U.S. LLC | $30.40 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $20.90 | 2025 | Alvesco |
| Hikma Pharmaceuticals USA | $17.24 | 2023 | Ryaltris |
| Circassia INC. | $15.58 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $14.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Butt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.